secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001104659-23-118064
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx reports Q3 net loss of $3.1M; ibezapolstat Phase 2 shows 96% cure rate, advancing to Phase 3
--------------------------------------------------------------------------------

- Net loss $3.1M ($0.24/diluted share) vs $3.5M ($0.32) in Q3 2022; cash $7.1M at Sept 30, 2023.
- Post-quarter warrant conversion raised $2.2M via ~680,000 shares issued.
- Ibezapolstat Phase 2 top-line: 96% (25/26) clinical cure rate at end of treatment; no safety concerns.
- Company preparing for End-of-Phase 2 FDA meeting and Phase 3 initiation.
- R&D expenses $1.3M in Q3 (down from $1.6M); G&A $1.8M (down from $2.0M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465923118064/0001104659-23-118064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465923118064/tm2330757d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-118064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer